JP4044839B2 - 異常細胞増殖を治療するための置換２環式誘導体 - Google Patents

異常細胞増殖を治療するための置換２環式誘導体 Download PDF

Info

Publication number
JP4044839B2
JP4044839B2 JP2002504233A JP2002504233A JP4044839B2 JP 4044839 B2 JP4044839 B2 JP 4044839B2 JP 2002504233 A JP2002504233 A JP 2002504233A JP 2002504233 A JP2002504233 A JP 2002504233A JP 4044839 B2 JP4044839 B2 JP 4044839B2
Authority
JP
Japan
Prior art keywords
methyl
yloxy
phenylamino
pyridin
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002504233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501139A (ja
Inventor
チャールズ カース ジョン
クマール バッタチャルヤ サミット
モ−リス ジョエル
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2004501139A publication Critical patent/JP2004501139A/ja
Application granted granted Critical
Publication of JP4044839B2 publication Critical patent/JP4044839B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
JP2002504233A 2000-06-22 2001-06-14 異常細胞増殖を治療するための置換２環式誘導体 Expired - Fee Related JP4044839B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21313600P 2000-06-22 2000-06-22
PCT/IB2001/001046 WO2001098277A2 (en) 2000-06-22 2001-06-14 Substituted bicyclic derivatives for the treatment of abnormal cell growth

Publications (2)

Publication Number Publication Date
JP2004501139A JP2004501139A (ja) 2004-01-15
JP4044839B2 true JP4044839B2 (ja) 2008-02-06

Family

ID=22793862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002504233A Expired - Fee Related JP4044839B2 (ja) 2000-06-22 2001-06-14 異常細胞増殖を治療するための置換２環式誘導体

Country Status (42)

Country Link
US (2) US6890924B2 (cg-RX-API-DMAC7.html)
EP (1) EP1292591B1 (cg-RX-API-DMAC7.html)
JP (1) JP4044839B2 (cg-RX-API-DMAC7.html)
KR (1) KR100545537B1 (cg-RX-API-DMAC7.html)
CN (3) CN1437594A (cg-RX-API-DMAC7.html)
AP (1) AP2001002192A0 (cg-RX-API-DMAC7.html)
AR (1) AR032353A1 (cg-RX-API-DMAC7.html)
AT (1) ATE288431T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001264159A1 (cg-RX-API-DMAC7.html)
BG (1) BG107269A (cg-RX-API-DMAC7.html)
BR (1) BR0111548A (cg-RX-API-DMAC7.html)
CA (1) CA2413424C (cg-RX-API-DMAC7.html)
CZ (1) CZ20023951A3 (cg-RX-API-DMAC7.html)
DE (1) DE60108754T2 (cg-RX-API-DMAC7.html)
DK (1) DK1292591T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ3407A1 (cg-RX-API-DMAC7.html)
EA (1) EA005525B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP024393A (cg-RX-API-DMAC7.html)
EE (1) EE200200710A (cg-RX-API-DMAC7.html)
ES (1) ES2236240T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20063831B (cg-RX-API-DMAC7.html)
HR (1) HRP20021005A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0301120A2 (cg-RX-API-DMAC7.html)
IL (1) IL152985A0 (cg-RX-API-DMAC7.html)
IS (1) IS6616A (cg-RX-API-DMAC7.html)
MA (1) MA26914A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA02012870A (cg-RX-API-DMAC7.html)
MY (1) MY127181A (cg-RX-API-DMAC7.html)
NO (1) NO20026166D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ522568A (cg-RX-API-DMAC7.html)
OA (1) OA12291A (cg-RX-API-DMAC7.html)
PA (1) PA8520301A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020257A1 (cg-RX-API-DMAC7.html)
PL (1) PL359557A1 (cg-RX-API-DMAC7.html)
PT (1) PT1292591E (cg-RX-API-DMAC7.html)
SK (1) SK17102002A3 (cg-RX-API-DMAC7.html)
SV (1) SV2002000504A (cg-RX-API-DMAC7.html)
TN (1) TNSN01091A1 (cg-RX-API-DMAC7.html)
UA (1) UA73990C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001098277A2 (cg-RX-API-DMAC7.html)
YU (1) YU95102A (cg-RX-API-DMAC7.html)
ZA (1) ZA200210231B (cg-RX-API-DMAC7.html)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
EP1117653B1 (en) 1998-10-01 2003-02-05 AstraZeneca AB Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
AU2001264159A1 (en) * 2000-06-22 2002-01-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
DE60237145D1 (de) * 2001-02-21 2010-09-09 Mitsubishi Tanabe Pharma Corp Chinazolinderivate
US20030144308A1 (en) * 2001-09-24 2003-07-31 Bauer Paul H. Fructose 1,6-bisphosphatase inhibitors
CA2462149C (en) * 2001-11-30 2010-06-22 Pfizer Products Inc. Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
EA007412B1 (ru) * 2001-12-12 2006-10-27 Пфайзер Продактс Инк. Соли е-2-метокси-n-(3-(4-(3-метилпиридин-3-илокси)фениламино)хиназолин-6-ил-аллил)ацетамида, их получение и их применение против рака
EP1465632A1 (en) * 2001-12-12 2004-10-13 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
AU2003291394B2 (en) 2002-11-20 2009-06-25 Array Biopharma, Inc Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
PL377686A1 (pl) * 2002-12-18 2006-02-06 Pfizer Products Inc. Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek
CA2509140A1 (en) * 2002-12-19 2004-07-08 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
RU2005125607A (ru) * 2003-04-09 2006-03-27 Пфайзер Продактс Инк. (Us) Способы получения производных n(пиридинилокси)-фениламино)хиназолинил)аллил)ацетамида и родственных соединений, а также промежуточные соединения для таких способов и способы получения таких соединений
MXPA05012839A (es) * 2003-05-27 2006-05-17 Pfizer Prod Inc Quinazolinas y pirido[3,4-d] pirimidinas como inhibidores de receptores tirosina quinasa.
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
NZ544472A (en) * 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
JP2007533596A (ja) * 2003-07-15 2007-11-22 ナショナル・リサーチ・カウンシル・オブ・カナダ 異常増殖性皮膚細胞を特徴とする状態の処置のためのヒト副甲状腺ホルモンの環状アナログ
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CA2535614C (en) * 2003-08-14 2009-12-22 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN1838959A (zh) * 2003-08-18 2006-09-27 辉瑞产品公司 Erbb2抗癌剂的给药方案
BRPI0414489A8 (pt) 2003-09-16 2019-01-15 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
ES2436888T3 (es) * 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
JP2007510708A (ja) * 2003-11-06 2007-04-26 ファイザー・プロダクツ・インク 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US7632840B2 (en) 2004-02-03 2009-12-15 Astrazeneca Ab Quinazoline compounds for the treatment of hyperproliferative disorders
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
EP1802341A1 (en) 2004-07-16 2007-07-04 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
JPWO2006025490A1 (ja) * 2004-09-01 2008-05-08 田辺三菱製薬株式会社 分子シャペロン機能調節剤
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
UA95775C2 (uk) 2005-04-26 2011-09-12 Пфайзер Инк. Антитіло, яке специфічно зв'язується з р-кадгерином
US20080194596A1 (en) * 2005-06-03 2008-08-14 Frizer Inc. Therapeutic Combination Including a Selective Erbb2 Inhibitor
EP1896451A2 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Bicyclic derivatives for the treatment of abnormal cell growth
AP2013006963A0 (en) 2005-09-07 2013-07-31 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like Kinase-1
KR101086967B1 (ko) 2005-11-15 2011-11-29 어레이 바이오파마 인크. 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물
GB0526552D0 (en) * 2005-12-29 2006-02-08 Morvus Technology Ltd New use
MEP43308A (en) 2006-05-09 2011-02-10 Pfizer Prod Inc Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
WO2008002039A1 (en) * 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting the growth of cancer cell
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
SG174774A1 (en) * 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
US20080221132A1 (en) * 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
RU2009126576A (ru) 2006-12-12 2011-01-20 Такеда Фармасьютикал Компани Лимитед (Jp) Конденсированное гетероциклическое соединение
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
EP2851091B1 (en) 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
EP2245026B1 (de) 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TW200944528A (en) 2008-03-12 2009-11-01 Takeda Pharmaceutical Fused heterocyclic compound
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
JP2013503846A (ja) 2009-09-01 2013-02-04 ファイザー・インク ベンズイミダゾール誘導体
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
CA2813162C (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2- derivatives as smoothened receptor modulators
BR112014006840A2 (pt) 2011-09-22 2017-04-04 Pfizer derivados de pirrolopirimidina e purina
CN102872018B (zh) * 2012-10-23 2015-07-15 广州市恒诺康医药科技有限公司 酪氨酸激酶不可逆抑制剂及其制备方法和用途
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
PE20161436A1 (es) 2014-04-30 2017-01-08 Pfizer Derivados de diheterociclo enlazado a cicloalquilo
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
JP6914860B2 (ja) 2015-07-01 2021-08-04 カリフォルニア インスティチュート オブ テクノロジー カチオン性粘液酸ポリマー系デリバリーシステム
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
JP6791979B2 (ja) * 2016-03-01 2020-11-25 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP7483193B2 (ja) 2018-06-13 2024-05-15 カリフォルニア・インスティテュート・オブ・テクノロジー 血脳バリアを越えるためのナノ粒子とそれを用いた治療法
LT3853220T (lt) 2018-09-18 2024-03-12 F. Hoffmann-La Roche Ag Chinazolino dariniai kaip antinavikiniai preparatai
TW202345816A (zh) * 2022-03-28 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類化合物、其製備方法及其在醫藥上的應用
TW202530231A (zh) * 2023-09-27 2025-08-01 大陸商江蘇恒瑞醫藥股份有限公司 喹唑啉衍生物的可藥用鹽、其結晶形式及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (cg-RX-API-DMAC7.html) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
PT1119567E (pt) 1998-10-08 2005-08-31 Astrazeneca Ab Derivados de quinazolina
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
AU2001264159A1 (en) * 2000-06-22 2002-01-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
HK1069576A1 (en) 2005-05-27
NO20026166L (no) 2002-12-20
EA005525B1 (ru) 2005-04-28
WO2001098277A2 (en) 2001-12-27
DK1292591T3 (da) 2005-05-30
US20050159435A1 (en) 2005-07-21
CN101348467A (zh) 2009-01-21
CN1576275A (zh) 2005-02-09
PL359557A1 (en) 2004-08-23
SV2002000504A (es) 2002-10-24
CA2413424C (en) 2007-10-02
PE20020257A1 (es) 2002-04-08
NZ522568A (en) 2004-12-24
AP2001002192A0 (en) 2002-12-21
WO2001098277A3 (en) 2002-06-13
AU2001264159A1 (en) 2002-01-02
GEP20063831B (en) 2006-05-25
DE60108754D1 (de) 2005-03-10
ES2236240T3 (es) 2005-07-16
UA73990C2 (en) 2005-10-17
DZ3407A1 (cg-RX-API-DMAC7.html) 2001-12-27
MXPA02012870A (es) 2003-05-14
OA12291A (en) 2004-03-18
EP1292591B1 (en) 2005-02-02
NO20026166D0 (no) 2002-12-20
CN1437594A (zh) 2003-08-20
YU95102A (sh) 2005-11-28
DE60108754T2 (de) 2005-06-23
US7332493B2 (en) 2008-02-19
KR20030016303A (ko) 2003-02-26
PA8520301A1 (es) 2003-06-30
CZ20023951A3 (cs) 2004-01-14
ZA200210231B (en) 2004-02-12
IL152985A0 (en) 2003-06-24
TNSN01091A1 (fr) 2005-11-10
HRP20021005A2 (en) 2004-02-29
PT1292591E (pt) 2005-06-30
BG107269A (bg) 2003-06-30
MY127181A (en) 2006-11-30
AR032353A1 (es) 2003-11-05
EA200201277A1 (ru) 2003-06-26
IS6616A (is) 2002-11-14
US20020169165A1 (en) 2002-11-14
BR0111548A (pt) 2003-05-06
CN1330640C (zh) 2007-08-08
SK17102002A3 (sk) 2004-04-06
HUP0301120A2 (hu) 2003-08-28
EP1292591A2 (en) 2003-03-19
KR100545537B1 (ko) 2006-01-25
CA2413424A1 (en) 2001-12-27
MA26914A1 (fr) 2004-12-20
EE200200710A (et) 2004-06-15
US6890924B2 (en) 2005-05-10
ECSP024393A (es) 2003-02-06
ATE288431T1 (de) 2005-02-15
JP2004501139A (ja) 2004-01-15

Similar Documents

Publication Publication Date Title
JP4044839B2 (ja) 異常細胞増殖を治療するための置換２環式誘導体
US7585869B2 (en) Substituted heterocylces for the treatment of abnormal cell growth
JP4181502B2 (ja) 異常な細胞増殖を治療するためのキナゾリン誘導体
JP4551771B2 (ja) 抗増殖剤として有効な新規ベンゾイミダゾール誘導体
US20050101618A1 (en) Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer
US20080194596A1 (en) Therapeutic Combination Including a Selective Erbb2 Inhibitor
JP2006513179A (ja) 異常細胞増殖の治療のための４−アニリノキナゾリン誘導体
US6927220B2 (en) Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
HK1069576B (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071116

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101122

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101122

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101122

Year of fee payment: 3

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101122

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101122

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111122

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees